(STRO) – Company Press Releases
-
Sutro Biopharma Reports Full Year 2023 Financial Results, Business Highlights and Select Anticipated Milestones
-
Sutro Biopharma to Participate in Upcoming Investor Conferences
-
Sutro Biopharma Highlights Potential Multi-Cancer Opportunity for Luvelta, a FolRα-targeting ADC
-
Sutro Biopharma to Host Investor Webcast Highlighting Potential Multi-Cancer Opportunity for Luvelta, a FolRα-targeted ADC, on January 4, 2024
-
Sutro Biopharma Announces New Positive Data from the Compassionate Use of Luveltamab Tazevibulin (luvelta) in Pediatric Patients with Relapsed/Refractory CBF/GLIS Presented at ASH 2023
-
Sutro Biopharma to Participate in the JMP Securities Hematology and Oncology Summit
-
Vaxcyte Exercises Option and Enters into Manufacturing Rights Agreement with Sutro Biopharma to Obtain Control Over Manufacturing and Development of Cell-Free Extract for its Vaccine Candidates
-
Sutro Biopharma Promotes Jane Chung to President and Chief Operating Officer
-
Sutro Biopharma Reports Third Quarter 2023 Financial Results, Business Highlights and Select Anticipated Milestones
-
Sutro Biopharma Announces Presentation of Data for Luveltamab Tazevibulin (luvelta) from the Phase 1 Dose-Expansion Study in Endometrial Cancers at ESMO 2023
-
Sutro Demonstrates Meaningful ADC Innovation with Five Presentations and One Poster at the 14th Annual World ADC Conference
-
Sutro Biopharma Appoints Dr. Hans-Peter Gerber as Chief Scientific Officer
-
Sutro Biopharma to Participate in Upcoming Investor Conferences
-
Sutro Biopharma Reports Second Quarter 2023 Financial Results, Business Highlights and Select Anticipated Milestones
-
Sutro Biopharma and Blackstone Announce Royalty Financing Collaboration
-
Sutro Biopharma Announces Oral Presentation at ASCO 2023 Featuring Data for Luveltamab Tazevibulin from the Phase 1 Dose-Expansion Study in Ovarian Cancer and the Initiation of the Phase 2/3 Pivotal S
-
Sutro Biopharma to Participate in the Jefferies Healthcare Conference
-
Sutro Biopharma Reports First Quarter 2023 Financial Results, Business Highlights and Select Anticipated Milestones
-
Sutro Biopharma to Present at the JMP Securities Life Sciences Conference
-
Sutro Biopharma Announces the Departure of President of Research & Chief Scientific Officer
-
Sutro Biopharma Presents Preclinical Data for its ROR1 Targeting Antibody Drug Conjugate STRO-003 at the AACR Annual Meeting 2023
-
Sutro Biopharma Reports Full Year 2022 Financial Results, Business Highlights and Select Anticipated Milestones
-
Sutro Biopharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Sutro Biopharma to Present at the Cowen 43rd Annual Health Care Conference
-
Sutro Biopharma Appoints Dr. Anne Borgman as Chief Medical Officer
-
Sutro Biopharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Sutro Biopharma Announces Update from STRO-002, Luveltamab Tazevibulin (Luvelta), Phase 1 Dose-Expansion Study and Registrational Plans in Advanced Ovarian Cancer
-
Sutro Biopharma to Present at the 41st Annual J.P. Morgan Healthcare Conference
-
Sutro Biopharma to Provide Data Update on STRO-002 and Plans for Registrational Path Forward in Advanced Ovarian Cancer
-
Sutro Biopharma and Vaxcyte Enter into Option Grant Agreement for the Development and Manufacturing Rights of Cell-Free Extract
-
Sutro Biopharma Announces Presentation of STRO-002 Data from the Compassionate Use Program in Pediatric Patients with Relapsed/Refractory CBF/GLIS AML at ASH 2022
-
Sutro Biopharma to Participate in Upcoming Investor Conferences
-
Sutro Biopharma Reports Third Quarter 2022 Financial Results, Business Highlights and Select Anticipated Milestones
-
Sutro Biopharma Announces Oral Presentation at the 64th American Society of Hematology Annual Meeting and Exposition
-
Sutro Biopharma to Participate in Upcoming Investor Conferences
-
StrongPoint Becomes AutoStore Distributor in UK and Ireland
-
Sutro Biopharma Announces Departure of Chief Medical Officer
-
World’s First AutoStore Solution With Frozen Food Zone to Be Installed by StrongPoint
-
World’s First AutoStore Solution With Frozen Food Zone to Be Installed by StrongPoint
-
Sutro Biopharma to Present at the 2022 Wells Fargo Healthcare Conference
-
Sutro Biopharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Sutro Biopharma Reports Second Quarter 2022 Financial Results, Business Highlights and Anticipated Milestones
-
Sutro Biopharma to Present at the 2022 Wedbush PacGrow Healthcare Conference
-
Sutro Biopharma Achieves “First in Human” Milestone in Cytokine Derivatives Collaboration with Merck
-
Sutro Biopharma Announces Virtual Deep Dive Research Forum: Next-Gen Innovations in ADCs
-
Astellas and Sutro Biopharma Announce Worldwide Strategic Collaboration to Advance Novel Immunostimulatory Antibody-Drug Conjugates (iADCs)
-
Astellas and Sutro Biopharma Announce Worldwide Strategic Collaboration to Advance Novel Immunostimulatory Antibody-Drug Conjugates (iADCs)
-
Sutro Biopharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
Sutro Biopharma to Participate in Upcoming Investor Conferences
-
Sutro Biopharma Reports First Quarter 2022 Financial Results, Business Highlights, and Anticipated Milestones
Back to STRO Stock Lookup